STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

CORT insider trade on 11/03/2025: 20,000 shares sold

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) officer Sean Maduck exercised stock options for 20,000 shares at $8.27 on 11/03/2025, then sold 20,000 shares at a weighted average price of $73.9908. The sale was made pursuant to a Rule 10b5-1 plan adopted on 09/05/2024.

After these transactions, he directly holds 7,904 shares and 261,986 stock options. Indirect holdings are 59,717 shares via the Sean and Molly Maduck Living Trust, 40,000 shares via the SNM 2025 GRAT, and 10,000 shares via Duckhill Capital, LLC.

Positive

  • None.

Negative

  • None.
Insider Maduck Sean
Role See Remarks
Sold 20,000 shs ($1.48M)
Type Security Shares Price Value
Exercise Stock option (right to buy) 20,000 $0.00 --
Exercise Common Stock 20,000 $8.27 $165K
Sale Common Stock 20,000 $73.9908 $1.48M
holding Common Stock -- -- --
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock option (right to buy) — 261,986 shares (Direct); Common Stock — 27,904 shares (Direct); Common Stock — 59,717 shares (Indirect, See Footnote)
Footnotes (1)
  1. Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $74.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Fully exercisable.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maduck Sean
(Last) (First) (Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CA 94065
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/03/2025 M 20,000 A $8.27 27,904(1) D
Common Stock 11/03/2025 S(2) 20,000 D $73.9908(3) 7,904(1) D
Common Stock 59,717 I See Footnote(4)
Common Stock 40,000 I See Footnote(5)
Common Stock 10,000 I See Footnote(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $8.27 11/03/2025 M 20,000 (7) 02/10/2027 Common Stock 20,000 $0.00 261,986 D
Explanation of Responses:
1. Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $74.27 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
5. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
6. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
7. Fully exercisable.
Remarks:
President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction was reported for CORT?

Officer Sean Maduck exercised 20,000 stock options at $8.27 and sold 20,000 shares at a weighted average price of $73.9908 on 11/03/2025.

Was the CORT insider sale under a 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 plan adopted on 09/05/2024.

How many CORT shares does the insider hold directly after the trade?

He directly holds 7,904 shares and 261,986 stock options following the transactions.

What are the insider’s indirect CORT holdings?

Indirect holdings include 59,717 shares (Living Trust), 40,000 shares (SNM 2025 GRAT), and 10,000 shares (Duckhill Capital, LLC).

What price were the CORT shares sold at?

The reported weighted average sale price was $73.9908, with actual prices ranging from $73.47 to $74.27 per share.

What is the insider’s role at Corcept Therapeutics?

He is listed as President, Corcept Endocrinology.